Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 586 to 600 of 2548 results for methods

  1. Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy ID6482 [ID6482]

    In development Reference number: GID-TA11625 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Identification and monitoring:- What are the most effective and cost-effective methods of increasing uptake of type 2 diabetes risk assessments and monitoring among those at greatest risk? Those at greatest risk include people from lower socioeconomic and black and minority ethnic groups, and those aged 75 or over.

    Identification and monitoring:- What are the most effective and cost-effective methods of increasing uptake of type 2 diabetes risk...

    Research recommendation
    Published
    9 June 2015

  3. Ensitrelvir for treating COVID-19 [ID6231]

    In development Reference number: GID-TA11224 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer [ID6526]

    In development Reference number: GID-TA11502 Expected publication date:  02 December 2026

    Technology appraisal guidance
    In development

  5. Lutetium-177 vipivotide tetraxetan in combination for treating PSMA-positive hormone-sensitive metastatic prostate cancer [ID6589]

    In development Reference number: GID-TA11766 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Insulin efsitora alfa for treating type 2 diabetes ID6499

    In development Reference number: GID-TA11644 Expected publication date:  22 October 2026

    Technology appraisal guidance
    In development

  7. Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer with papillary tumours or carcinoma in situ untreated with BCG ID6454

    In development Reference number: GID-TA11592 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Icotrokinra for treating moderate to severe plaque psoriasis in people 12 years and over ID6579

    In development Reference number: GID-TA11780 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Setmelanotide for treating acquired hypothalamic obesity in people 4 years and over ID6542: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 16 January 2026.

    Technology appraisal guidance
    In consultation

  10. Filgotinib for treating axial spondyloarthritis ID6594: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 21 January 2026.

    Technology appraisal guidance
    In consultation

  11. Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]

    Awaiting development Reference number: GID-TA10605 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]

    Awaiting development Reference number: GID-TA10657 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6428]

    Awaiting development Reference number: GID-TA11538 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254]

    Awaiting development Reference number: GID-TA11281 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source [ID1417]

    Awaiting development Reference number: GID-TA10426 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development